ERJ Open Research · 2021 · 77 citations · 23 references
MedicineInternal MedicineClinical EpidemiologyEpidemiologic MethodsPulmonologyCase DefinitionFibrosisInterstitial Lung DiseasePulmonary PathologyRespiratory DiseaseAggregate Data AssessmentFibrotic Interstitial Lung DiseaseInterstitial Lung Disease ClassificationInterstitital Lung DiseaseLung DiseasesPrevalent Case IdentificationProgressive Pulmonary FibrosisPulmonary Fibrosis Progression
The PERSEIDS study aimed to estimate incidence/prevalence of interstitial lung diseases (ILDs), fibrosing interstitial lung diseases (F-ILDs), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated ILD (SSc-ILD), other non-IPF F-ILDs and their progressive-fibrosing (PF) forms in six European countries, as current data are scarce. This retrospective, two-phase study used aggregate data (2014–2018). In Phase 1, incident/prevalent cases of ILDs above were identified from clinical databases through an algorithm based on codes/keywords, and incidence/prevalence was estimated. For non-IPF F-ILDs, the relative percentage of subtypes was also determined. In Phase 2, a subset of non-IPF F-ILD cases was manually reviewed to determine the percentage of PF behaviour and usual interstitial pneumonia-like (UIP-like) pattern. A weighted mean percentage of progression was calculated for each country and used to extrapolate incidence/prevalence of progressive-fibrosing ILDs (PF-ILDs). In 2018, incidence/10 5 person-years ranged between 9.4 and 83.6 (ILDs), 7.7 and 76.2 (F-ILDs), 0.4 and 10.3 (IPF), 6.6 and 71.7 (non-IPF F-ILDs), and 0.3 and 1.5 (SSc-ILD); and prevalence/10 5 persons ranged between 33.6 and 247.4 (ILDs), 26.7 and 236.8 (F-ILDs), 2.8 and 31.0 (IPF), 22.3 and 205.8 (non-IPF F-ILDs), and 1.4 and 10.1 (SSc-ILD). Among non-IPF F-ILDs, sarcoidosis was the most frequent subtype. PF behaviour and UIP-like pattern were present in a third of non-IPF F-ILD cases each and hypersensitivity pneumonitis showed the highest percentage of progressive behaviour. Incidence of PF-ILDs ranged between 2.1 and 14.5/10 5 person-years, and prevalence between 6.9 and 78.0/10 5 persons. To our knowledge, PERSEIDS is the first study assessing incidence, prevalence and rate of progression of ILDs across several European countries. Still below the threshold for orphan diseases, the estimates obtained were higher and more variable than reported in previous studies, but differences in study design/population must be considered.
23
Ganesh Raghu, Harold R. Collard, Jim Egan et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 7.3K citations · Full text
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text
Ganesh Raghu, Martine Rémy‐Jardin, Christopher J. Ryerson et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 1K citations · Full text
Demosthenes Bouros, Athol U. Wells, Andrew G. Nicholson et al. · American Journal of Respiratory and Critical Care Medicine · 2002 · 820 citations